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In a previous work we have demonstrated the antimicrobial activity of ferrocenyl or phenyl derivatives of diphenyl
butene series. This finding has opened a new area of applications of organometallic compounds.
In order to improve these activities, we have synthesized new organic and organometallic diaryl butene
compounds with different lengths of their amino chains. These new compounds, and also their ammonium salts,
were tested against man pathogenic microorganisms Escherichia coli (ATCC 10536), Pseudomonas aeruginosa
(ATCC 15442), Staphylococcus aureus (ATCC 6538) and Enterococcus hirae (ATCC 10541).
It emerged from the tests that the Gram+ bacteria are more sensitive to the compounds than Gram-, and the
compounds with 3 carbon amino chains have a better antimicrobial activity than the one having a chain of 2 or
4 carbons.
The transformation of compounds to citrate salts was accompanied by a significant regression of antibacterial
activity against Pseudomonas aeruginosa, for both organic and ferrocenic molecules. This resistance problem has
been solved using hydrochlorides salts rather than citrates one.
Keywords: Diaryl butene; Antimicrobial activity; Citrate formulation; Citrate salts resistance;
Hydrochlorides formulationIntroduction
According to global risk report published in 2013,
antibiotic-resistant infections kill every year 100,000
Americans, 80,000 Chinese and 25,000 Europeans
(Spellberg et al. 2011; Howell 2013). In fact, infections
cost 21 to 34 Bn US$/year in USA and 1,5 Bn Euro/year
in Europe.
The frequency of antibiotic resistance is profoundly
different from one European country to another. Europe
was subject of an antibiotherapy study (ICAAC), made* Correspondence: mehdi_arbi@yahoo.fr
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in any medium, provided the original work is pby the team of Prof Voss, presented in 1992 to the U.S.
Congress and published few years later (Voss et al.
1994). This study showed considerable differences in
resistance rates of Staphylococcus aureus to meticillin
(MRSA) between European countries, with rates ranging
from 0% in some northern countries (Finland, Denmark,
Sweden) to 35% and 40% in some countries that are
more "Latin" (Italy, France). In some countries, MRSA
studies, (Voss et al. 1994; Goldstein and Acar 1995)
show that almost all strains were resistant to other anti-
biotics, especially quinolones and rifampicin. Resistance
of Staphylococcus aureus to meticillin increased also in
the most medically-advanced countries, even in United
States of America (Gaynes et al. 1993). Every year MRSA
kills 19,000 USA patients (more than emphysema, HIV/
AIDS, Parkinson’s disease, and homicide combined).open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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lished by World economic forum, demonstrates a de-
crease on the rate of MRSA infections from 2008 to
2011 in the UK, Germany, Belgium, France and Spain to
reach a rate included between 10% and 25%, this rate in-
creased in Hungary and Slovakia (25% to < 50%). In
Portugal and Romania MRSA infections statistics are the
highest with a rate up to 50%. In addition, the increase
of resistance rates for Gram negative bacilli such as
Klebsiella pneumoniae in all Europe has been reported.
This germ shows resistance to three classes of antibiotics
combination (3rd generation cephalo-sporins, fluoroqui-
nolones and aminoglycosides) with rates included be-
tween 1% and up to 50%. A resistance that can be
explained by production of β-lactamase with extended
spectrum (Sirot et al. 1993; Burwin et al. 1994). Some
countries are also faced with epidemic phenomena asso-
ciated with the two species of gram-negative willingly
multiresistant bacilli Acinetobacter baumannii and Ste-
notrophomonas maltophilia (Lortholary et al. 1995).
In Spain and France, an increase of pneumococcal re-
sistance to penicillin has been reported (Pallares et al.
1995). This increase is due to the appearance of resistant
gram positive cocci like Pneumococci (Pallares et al.
1995) and Enterococci (Spellberg et al. 2011; Howell
2013).
Clinical resistance is a complex phenomenon and its
manifestation is dependent on many factors, but hospi-
tals are not the only places where bacterial resistance
can be developed. The use of biocides in agriculture and
antibiotics in animal husbandry are two causes that ac-
centuate the problem.
Allergy is one of the unpredictable problems as-
sociated with antibiotics use. This hypersensitivity is a
drug reaction that is usually related to either the dose or
the pharmacological action of the drug (Solensky 2006;
Volcheck 2004). It accounts for approximately 6-10% of
all adverse drug reactions and the classes of antibiotics
that are most commonly associated with allergic reac-
tions are penicillins, cephalosporins, sulfonamides and
macrolides (Gruchalla 2003).
To overcome drug resistance and to find new types of
drugs, researchers have been exploring the possibility of
using transition metal complexes as drugs against di-
verse diseases (Jaouen 2006; Hillard and Jaouen 2011;
Patra et al. 2012; Gasser and Metzler-Nolte 2012; Chavin
and Biot 2010; Hartinguer et al. 2009; Omelas 2011).
Ferrocenyl or phenyl derivatives of diphenyl butene
series, tamoxifen analogues, known for their antitumor
activity (Jaouen et al. 2000), showed also an excellent
antimicrobial activity against Escherichia coli, Pseudomo-
nas aeruginosa, Staphylococcus aureus and Enterococcus
hirae (El Arbi et al. 2011). This finding, supported by
published results of an American team regarding theefficacy of tamoxifen against Candida albicans (Dolan
et al. 2009), opens a new area of applications to this type
of compounds.
Bacterial resistance problems, the inefficiency of anti-
biotics discovered many years ago, the dual role of anti-
biotics in combating infectious and cancer diseases and
the problem of allergy are good reasons to expend more
efforts on the discovery of new active molecules.
On the same vision, this work has as objectives the
synthesis of various diphenyl butene compounds with
two amino chains, the exploration of the most effective
structure microbiologically and the best appropriate for-
mulation to make it water-soluble.Materials and methods
Synthesis and characterization of compounds
The synthesis of all compounds was performed under an
argon atmosphere, using standard Schlenk techniques.
Anhydrous THF (tetrahydrofurane) was obtained by dis-
tillation from sodium/benzophenone. Thin layer chro-
matography was performed on silica gel 60 GF254.
Infrared spectra were obtained on FT/IR-4100 JASCO
spectrometers (http://www.jascofrance.fr). 1H and 13C
NMR spectra were recorded on a 300 MHz Bruker spec-
trometer (http://www.bruker.com). Mass spectrometry
was performed with a Nermag R 10-10C spectrometer.
Elemental analyses were performed by the microanalysis
service of CNRS at Gif – sur – Yvette (https://www.
imagif.cnrs.fr). The preparative HPLC (high performance
liquid chromatography) separations were performed on
a Shimadzu apparatus (http://www.shimadzu.fr) with a
Nucleodur C18 column (length of 25 cm, diameter of
2.5 cm, and particle size of 10 μm).1-[Bis(4-hydroxyphenyl)methylidenyl]indan 10
Titanium chloride (15.177 g, 8.79 mL, 80 mmoles) was
added dropwise to a suspension of zinc powder (7.844 g,
120 mmoles) in dry THF (200 mL) at 0-20°C. The
mixture was heated at reflux for 2 hours. A second so-
lution was prepared by dissolving 1-indanone (2.643 g,
20 mmoles) and 4,4'-dihydroxybenzophenone (4.284 g,
20 mmoles) in dry THF (50 mL). This latter solution
was added dropwise and the reflux was continued over-
night. After cooling, the mixture was poured in water
and dichloromethane was added. The mixture was aci-
dified with diluted hydrochloric acid until dark color
disappeared and was decanted. The aqueous layer was
extracted with dichloromethane and the combination of
organic layers was dried over magnesium sulphate. After
concentration under reduced pressure, the crude prod-
uct was chromatographed on silica gel column with a
mixture of cyclohexane and ethyle acetate 50/50 as the
eluent to give 10 as a white solid with a 79% yield. The
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the literature (Kim and Katzenellenbogen 2000).
1-[Bis(4-{3-dimethylaminopropoxy}phenyl)methylidenyl]
indan 4
Compound 10 (1.886 g, 6mmol), potassium carbonate
(8.29 g, 60 mmol) and cesium carbonate (3.91 g, 12 mmol)
were stirred in 120 mL of acetone, then 3-dimethylamino-
1-propyl chloride hydrochloride (5.69 g, 36 mmol) was
added. The mixture was refluxed overnight, cooled and
concentrated under reduced pressure. The residue was
extracted with a mixture of dichloromethane and water,
then was decanted. The organic layer was washed twice
with a diluted aqueous solution of sodium hydroxide
followed with water, dried over magnesium sulphate then
was concentrated under reduced pressure. The mixture
was purified by HPLC using a 10% trietylamine solution
in methanol to give 4 as oil with a 67% yield.
1H NMR (CDCl3) : δ 1.87-2.06 (m, 4 H, CH2), 2.27
(s, 6 H, NMe2), 2.28 (s, 6 H, NMe2), 2.41-2.55 (m, 4 H,
CH2N), 2.93 (s, 4 H, Hindane), 3.95-4.09 (m, 4 H, CH2O),
6.50 (d, J = 7.7 Hz, 1 H, Harom), 6.78-6.92 (m, 5 H,
Harom), 7.01-7.25 (m, 6 H, Harom).
13C NMR (CDCl3) : δ
27.9 (2 CH2), 31.6 (CH2 indane), 34.8 (CH2 indane), 45.8
(2 NMe2), 56.7 (CH2N), 56.8 (CH2N), 66.5 (2 CH2O),
114.1 (2 CH C6H4), 114.9 (2 CH C6H4), 125.2 (CHindane),
125.3 (CHindane), 125.9 (CHindane), 127.3 (CHindane),
130.7 (2 CH C6H4), 131.4 (2 CH C6H4), 134.6 (C), 135.6
(C), 136.7 (C), 139.6 (C), 142.0 (C), 147.9 (C), 157.9 (C),
158.4 (C). IR (KBr, ν cm-1): 3063, 3033, 2940, 2854,







Diamino compound 5 (2.2 g, 3.7 mmol) was dissolved
into 200 mL of diethyl ether. A 2 M solution of
hydrochloric acid in diethyl ether (3.7 mL, 7.4 mmol)
was added dropwise into the solution. An orange pre-
cipitate was immediately formed. After stirring for 20
min, the mixture was filtered under argon and the
obtained orange solid was washed with 3 × 5 mL of
diethyl ether and was dried under vacuum giving com-
pound 9 in 59% yield. Crystals contain traces of diethyl
ether.
1H NMR (DMSO-d6) : δ 1.02 (t, J = 7.4 Hz, 3 H, CH3),
2.04-2.27 (m, 4 H, 2 CH2), 2.44-2.63 (m, 2 H, CH2), 2.79
(s, 12 H, NMe2H
+), 3.10-3.30 (m, 4 H, CH2N), 3.85 (s, 2
H, C5H4), 3.97-4.25 (m, 11 H, C5H4 + C5H5 + CH2O),
6.86 (d, J = 8.0 Hz, 2 H, C6H4), 6.90-7.01 (m, 4 H,
C6H4), 7.14 (d, J = 8.0 Hz, 2 H, C6H4).
13C NMR
(DMSO-d6) : δ 16.3 (CH3), 24.8 (2 CH2), 28.1 (CH2),
42.9 (2 NMe2H+), 54.9 (2 CH2N), 65.6 (CH2O), 65.8
(CH2O), 68.8 (2 CH C5H4), 69.6 (2 CH C5H4), 69.9(5 CH C5H5), 86.8 (C C5H4), 115.1 (2 x 2 CH C6H4),
130.8 (2 CH C6H4), 131.3 (2 CH C6H4), 137.1 (C), 137.4
(C), 137.9 (C), 138.2 (C), 157.5 (2 C) IR (KBr, ν cm-1):
3425 (NH), 3029, 2960, 2685, 2510, 2470 (CH2, CH3).
Microbial strains
Known and newly synthesized compounds were tested
against Escherichia coli (ATCC 10536), Pseudomonas
aeruginosa (ATCC 15442), Staphylococcus aureus (ATCC
6538) and Enterococcus hirae (ATCC 10541).
All strains were cultured in liquid LB (1% Bactotryptone,
0.5% Yeast extract, 0.5% NaCl).
Estimation of the antimicrobial effect
The estimation of the antimicrobial effect against micro-
bial strains was performed by the method of micro-
dilution in ELISA plates. A 2.54 10-3 M stock solutions
of the tested products were prepared in DMSO or water,
depending on their solubility. In Elisa plates and for each
product a series of eight wells containing 100 μl of cul-
ture medium with decreasing concentration of the pro-
duct were prepared by the successive ½ dilution.
A 100 μl of overnight shaking microbial culture, incu-
bated at adequate temperature, depending on bacterial
strains, were used to inoculate the plate wells containing
different concentrations of compounds. The final con-
centration of each product, for a series of eight wells
was 2.54 10-4 M, 1.27 10-4 M, 6.35 10-5 M, 3.18 10-5 M,
1.59 10-5 M, 7.94 10-6 M, 3.97 10-6 M and 1.98 10-6 M.
The plates were incubated with shaking overnight at the
same temperature, depending on bacterial strains, and
their OD was measured at 620 nm.
A negative control (uninoculated wells), a positive con-
trol (seeded and without antimicrobial compound wells)
were prepared under the same experimental conditions.
The inhibitory activity of the tested compounds was
calculated according to the formula:
IA %ð Þ ¼ 100−100 OD 620 xð Þ=OD 620 ið Þð Þ
where (x) is the microbial culture containing the inhibi-
tor and (i) is the microbial culture without inhibitor.
Results
All compounds studied in the present work are shown
in Figure 1.
Synthesis
The synthesis of compounds 1 (Shiina et al. 2008), 2
(Pigeon et al. 2011), 5 (Pigeon et al. 2011), and 8
(El Arbi et al. 2011), has already been published. Com-
pounds 3, 6 and 7 are newly-synthesised products and
their synthesis will be published in the future.
Figure 1 Chemicals tested.
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first prepared by reacting 1-indanone with 4,4'-dihydro-
xybenzophenone in the McMurry coupling conditions.
This compound was converted into the diamine com-
pound 4 by heating at reflux 3-dimethylamino-1-propyl
chloride hydrochloride with 10 in acetone in thepresence of potassium carbonate and cesium carbonate
as bases. 4 was obtained in the yield of 67%.
Hydrochloride 9 was prepared by adding 2 equivalents
of hydrochloric acid to diamine compound 5 dissolved








Figure 2 Synthesis of compounds 4 and 10.
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To evaluate the impact of the amino chain length on the
antibacterial activity, organic compounds 1, 2 and 3,
having an amino chain of 2, 3 and 4 carbons, respec-
tively, were selected for the test with four bacteria. At a
concentration of 2.54 10-4M, as shown on Figure 4, all
tested strains were sensitive to the three compounds.
This result confirms again the activity of compound 3
(El Arbi et al. 2011). The tested compounds are effective
against Gram+ and Gram- strains, but not with the same
efficiency. Gram+ bacteria, Staphylococcus aureus and
Enterococcus hirae, seem to be more sensitive than
Gram- strains, Escherichia coli and Pseudomonas aeru-
ginosa. Therefore, there is a potential use against Gram+
bacterial infections for these compounds. Within these
compounds, the ones with 3 and 4 carbons are more po-
tent comparing to the one of 2 carbons. It is interesting
to note that these molecules increase the proliferation of
micro-organisms when used at low doses.
Effect of organic or organometallic compound on the
antimicrobial activity
It has been shown that ferrocenyl compounds are more
active than their organic analogues against cancer cells
(Top et al. 2003). It is interesting to see if this behavior
is also verified for the antibacterial activity. Therefore,
we compare now the activity of two organic compounds,
the compounds 2 and 4, to that of ferrocenic compound
5. As shown in Figure 5, all compounds are more active
against Gram+ than Gram- bacteria. The difference inFigure 3 Synthesis of compound 9.activity between organic and ferrocenic compounds is
clearly observed in the case of Staphylococcus aureus.
The inhibition percentage (IP) of 2 and 4 is about
94.32% at a dose of 3.59 10-5M while that of 5 is 7.94
10-6M. In the case of Enterococcus hirae, the IP value of
59.21% is obtained using 7.94 10-6M for both organic
compounds and 1,98 10-6M for organometallic com-
pound. Therefore, the organometallic compound 5 is
more potent, against Gram+ strains, than the organic
compounds (4.5 times for Staphylococcus aureus and 4
times for Enterococcus hirae).
Effect of the formulation of salts of citric acid on the
antimicrobial activity
Compounds 2, 4, 5 are not soluble in water. Their use
as antimicrobial agents may be more convenient if they
could be transformed into aqueous soluble forms. This
transformation was achieved by their conversion into
salts of citric acid. Thus, compounds 2, 4, and 5 were
converted into compounds 6, 7, and 8, respectively.
Figure 6 shows that the transformation of the com-
pounds into salts did not alter their activity except for
Pseudomonas aeruginosa. The activities against Staphylo-
coccus aureus and Enterococcus hirae were maintained.
We even observed an improvement of the antimicrobial
activity effect against Escherichia coli, compound 6 ex-
pressed an IP of 96.2% at a dose of 6.35 10-5M while 2
reaches this level of inhibition at a dose of 2.54 10-4M. By
contrast, the loss of effectiveness against Pseudomonas
aeruginosa was observed for all salts. Indeed, at the
1
2 3
(  )3 (  )4
(  )2
(  )2
(  )4(  )3
Figure 4 Antimicrobial activity of compounds 1, 2 and 3.
2 4 5
(  )3 (  )3
(  )3(  )3
(  )3
(  )3
Figure 5 Antimicrobial activity of compounds 2, 4 and 5.
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Figure 7 Antimicrobial activity of compounds 5, 8, 9 and Doxycycline.
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creased from 89%, 89.46% and 63.38% for 2, 4 and 5, to
32.7%, 5.6% and −2.7% for 6, 7, and 8, respectively.
Effect of the transformation to hydrochloride on the
antimicrobial activity
The loss of activity of the salts against Pseudomonas
aeruginosa prompted us to look for other salts forms of
compounds. Thus, compound 5 was converted into hy-
drochloric salt 9. Figure 7 shows that 9 preserved both
solubility in water and the compound 5 activity observed
against Staphylococcus aureus, Enterococcus hirae and
Escherichia coli. Interestingly, the loss of activity observed
against Pseudomonas aeruginosa following the conversion
of compound 5 into 8 was recovered by the compound 9.
Comparing to Doxycycline, an antibiotic of reference,
9 shows a similar activity and has an excellent antibac-
terial activity, especially against Gram+ (Figure 7).
Discussion
The present study confirms the importance of using
tamoxifen and tamoxifen analogues in microbial inhibi-
tion. We found that tamoxifen and ferrocifen derivatives
bearing two amino chains are active against bacteria.
The activity of compounds can be improved by varying
the length of the amino chain, the replacement of one of
the arene rings of tamoxifen by a ferrocenyl unit, and by
transforming the compounds into aqueous soluble
forms. Thus, compounds with 3 carbon amino chain are
more active than compounds with 2 and 4 carbon
chains. Ferrocene derivatives, the ferrocifen series, have
better activity than pure organic compounds (the tam-
oxifen series). Moreover, transforming the compounds
into ammonium salts make the compounds soluble in
water and improve the activity of compounds. For this
last purpose, hydrochloric salts should be used rather
than the citrate ones because of the resistance of Pseu-
domonas aeruginosa of this last salt form.
In addition to its antitumor efficacy, tamoxifen pos-
session of antimicrobial properties has been recently
reported (Dolan et al. 2009); meanwhile, knowing that
tamoxifen is marketed as tamoxifen citrate, we want to
warn following the results the possible ineffectiveness
against Pseudomonas aeruginosa and the risk of aggrava-
tion of nosocomial infections, caused among others, by
Pseudomonas aeruginosa.
We conclude that it is imperative to avoid the citrate salt
formulation for antimicrobial products, because of the loss
of compound activity against Pseudomonas aeruginosa.
We also recommend trying other types of formulation for
anti-tumor compounds, especially in the case of chemo-
therapy treatment, where citrate is used in low doses,
which can offer an advantage of proliferative effect for mi-
croorganisms and biofilm formation (Robert et al. 2006).Competing interests
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